120 related articles for article (PubMed ID: 18216152)
1. Rosuvastatin is additive to high-dose candesartan in slowing progression of experimental mesangioproliferative glomerulosclerosis.
Krämer S; Kron S; Wang-Rosenke Y; Loof T; Khadzhynov D; Morgera S; Kawachi H; Shimizu F; Martini S; Neumayer HH; Peters H
Am J Physiol Renal Physiol; 2008 Apr; 294(4):F801-11. PubMed ID: 18216152
[TBL] [Abstract][Full Text] [Related]
2. The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse.
Giunti S; Calkin AC; Forbes JM; Allen TJ; Thomas MC; Cooper ME; Jandeleit-Dahm KA
Am J Physiol Renal Physiol; 2010 Sep; 299(3):F528-35. PubMed ID: 20554645
[TBL] [Abstract][Full Text] [Related]
3. Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.
Engelhorn T; Doerfler A; Heusch G; Schulz R
Neurosci Lett; 2006 Oct; 406(1-2):92-6. PubMed ID: 16901636
[TBL] [Abstract][Full Text] [Related]
4. Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat.
Krämer S; Wang-Rosenke Y; Scholl V; Binder E; Loof T; Khadzhynov D; Kawachi H; Shimizu F; Diekmann F; Budde K; Neumayer HH; Peters H
Am J Physiol Renal Physiol; 2008 Feb; 294(2):F440-9. PubMed ID: 18094032
[TBL] [Abstract][Full Text] [Related]
5. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis.
Nakamura T; Obata J; Kimura H; Ohno S; Yoshida Y; Kawachi H; Shimizu F
Kidney Int; 1999 Mar; 55(3):877-89. PubMed ID: 10027924
[TBL] [Abstract][Full Text] [Related]
6. Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan.
Chen J; Li D; Schaefer R; Mehta JL
Atherosclerosis; 2006 Feb; 184(2):295-301. PubMed ID: 16005008
[TBL] [Abstract][Full Text] [Related]
7. The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation.
Calkin AC; Giunti S; Sheehy KJ; Chew C; Boolell V; Rajaram YS; Cooper ME; Jandeleit-Dahm KA
Diabetologia; 2008 Sep; 51(9):1731-40. PubMed ID: 18594792
[TBL] [Abstract][Full Text] [Related]
8. Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis.
Wang Y; Krämer S; Loof T; Martini S; Kron S; Kawachi H; Shimizu F; Neumayer HH; Peters H
Kidney Int; 2005 Jul; 68(1):47-61. PubMed ID: 15954895
[TBL] [Abstract][Full Text] [Related]
9. S1P modulator FTY720 limits matrix expansion in acute anti-thy1 mesangioproliferative glomerulonephritis.
Martini S; Krämer S; Loof T; Wang-Rosenke Y; Daig U; Budde K; Neumayer HH; Peters H
Am J Physiol Renal Physiol; 2007 Jun; 292(6):F1761-70. PubMed ID: 17356129
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril.
Krämer S; Loof T; Martini S; Rückert M; Wang Y; Böhler T; Shimizu F; Kawachi H; Neumayer HH; Peters H
Am J Physiol Renal Physiol; 2005 Aug; 289(2):F359-68. PubMed ID: 15769934
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effect of candesartan and rosuvastatin on CD40 and MMPs expression in apo-E knockout mice: novel insights into the role of RAS and dyslipidemia in atherogenesis.
Chen J; Li D; Schaefer RF; Mehta JL
J Cardiovasc Pharmacol; 2004 Oct; 44(4):446-52. PubMed ID: 15454852
[TBL] [Abstract][Full Text] [Related]
12. Selective lymphocyte inhibition by FTY720 slows the progressive course of chronic anti-thy 1 glomerulosclerosis.
Peters H; Martini S; Wang Y; Shimizu F; Kawachi H; Krämer S; Neumayer HH
Kidney Int; 2004 Oct; 66(4):1434-43. PubMed ID: 15458436
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinases inhibition by Imatinib slows progression in chronic anti-thy1 glomerulosclerosis of the rat.
Wang-Rosenke Y; Khadzhynov D; Loof T; Mika A; Kawachi H; Neumayer HH; Peters H
BMC Nephrol; 2013 Oct; 14():223. PubMed ID: 24119229
[TBL] [Abstract][Full Text] [Related]
14. Effects of rosuvastatin on glomerular capillary size-selectivity function in rats with renal mass ablation.
Corna D; Sangalli F; Cattaneo D; Carrara F; Gaspari F; Remuzzi A; Zoja C; Benigni A; Perico N; Remuzzi G
Am J Nephrol; 2007; 27(6):630-8. PubMed ID: 17851231
[TBL] [Abstract][Full Text] [Related]
15. Late angiotensin II receptor blockade in progressive rat mesangioproliferative glomerulonephritis: new insights into mechanisms.
Villa L; Boor P; Konieczny A; Kunter U; van Roeyen CR; Denecke B; Gan L; Neusser MA; Cohen CD; ; Eitner F; Scholl T; Ostendorf T; Floege J
J Pathol; 2013 Apr; 229(5):672-84. PubMed ID: 23192593
[TBL] [Abstract][Full Text] [Related]
16. Passive Heymann nephritis: evidence that angiotensin-converting enzyme inhibition reduces proteinuria and retards renal structural injury.
Zoja C; Corna D; Bruzzi I; Foglieni C; Bertani T; Remuzzi G; Benigni A
Exp Nephrol; 1996; 4(4):213-21. PubMed ID: 8983642
[TBL] [Abstract][Full Text] [Related]
17. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.
Zoja C; Corna D; Gagliardini E; Conti S; Arnaboldi L; Benigni A; Remuzzi G
Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1203-11. PubMed ID: 20719975
[TBL] [Abstract][Full Text] [Related]
18. Candesartan prevents the progression of mesangioproliferative nephritis in rats.
Nakamura T; Obata J; Onizuka M; Kimura H; Ohno S; Yoshida Y; Kawachi H; Shimizu F
Kidney Int Suppl; 1997 Dec; 63():S226-8. PubMed ID: 9407466
[TBL] [Abstract][Full Text] [Related]
19. Addition of the antioxidant probucol to angiotensin II type I receptor antagonist arrests progressive mesangioproliferative glomerulonephritis in the rat.
Kondo S; Shimizu M; Urushihara M; Tsuchiya K; Yoshizumi M; Tamaki T; Nishiyama A; Kawachi H; Shimizu F; Quinn MT; Lambeth DJ; Kagami S
J Am Soc Nephrol; 2006 Mar; 17(3):783-94. PubMed ID: 16467449
[TBL] [Abstract][Full Text] [Related]
20. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Ferdinand KC; Davidson MH; Kelly MT; Setze CM
Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
